Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Breaking oncometabolites dynamics for next-generation dendritic cells tumor immunotherapy

Project description

Oncometabolite dynamics for advanced dendritic cell tumour therapy

Immunotherapy harnesses the body’s immune system to fight cancer, highlighting the role of the tumour microenvironment (TME) in shaping immune responses. Manipulating tumour-derived metabolites, known as oncometabolites, may strengthen anti-tumour immunity. Research shows that deleting the aryl hydrocarbon receptor (AhR) in antigen-presenting cells can trigger tumour rejection, suggesting that AhR senses the composition of the TME and regulates immune activity. The ERC-funded REACT-DC project aims to identify metabolites in the TME that activate AhR and investigate their role in tumour rejection. It will also develop strategies to inhibit AhR or its downstream pathways in selected antigen-presenting cells using single-cell analysis, gene editing and computational chemistry, aiming to uncover therapeutic targets and prevent tumour escape.

Objective

"Owing to an increased appreciation of the potential for immunotherapy in neoplasia, much attention has been focuing on a greater understanding of the immune, bidirectional intricacies involving the Tumor MicroEnvironment (TME). Recent work has demonstrated that TME elicits environmental changes, metabolic in nature, in the host’s immune cells, that dampen their ability to REACT against tumors. Manipulating the biology of oncometabolites can strengthen an antitumor immune response as well as circumvent therapy resistance. Here I propose innovative modalities to tackle this problem. The Aryl hydrocarbon Receptor (AhR), best known as the receptor for dioxins, has recently been shown to be one ""central node"" for communication between host's cells and its ligands, disparate as the nature and source. I have recently found that selective AhR deletion in a subset of antigen presenting cells triggers the rejection of an otherwise progressive fibrosarcoma tumor in vivo. I thus hypothesize that, AhR, expressed in orchestrators of immune responsiveness, represents a key sensor of TME composition, influencing the outcome of an immune reaction against tumors. The main objective of this project is to identify AhR-activating metabolites in TME and disclose their impact on tumor rejection or progression. In parallel, I aim at developing novel advanced strategies, with a high degree of translatability to human cells, to specifically inhibit AhR or AhR-dependent programs in selected APCs. I will combine state-of-the-art technology with new and powerful technologies, including advanced single-cell analysis, promoter gene-editing approaches and computational chemistry. The potential of such a project is very high, because such metabolites may be predictors of immune activation or suppression in TME, and the downstream targets of those immunesuppressive oncometabiltes may represent druggable targets to inhibit tumor escape mechanisms."

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-STG

See all projects funded under this call

Host institution

UNIVERSITA DEGLI STUDI DI PERUGIA
Net EU contribution
€ 1 500 000,00
Address
PIAZZA DELL UNIVERSITA 1
06123 Perugia
Italy
Region
Centro (IT) Umbria Perugia
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 500 000,00

Beneficiaries (1)